Top Thai officials are pulling off their gloves against Pfizer Bio N Tech and could become the first country in the world to Nullify the contracts between the government and Pfizer.This would mean Pfizer would have to pay back billions of dollars because of their jabs to the Thai people.
“On December 15, about three weeks after her third Pfizer booster shot, Princess Bajrakitiyabha Narendira Debyavati collapsed with heart issues and went into a coma.
“The 44-year-old eldest daughter of the King in Thailand, and likely heir to the throne, had reported to be in excellent health prior to the vaccination and collapsed while training her dogs.
The media seemed to generally lose interest after a January 9 update in which it was reported the princess remained in a coma and, according to the palace, has now been diagnosed with “severe heart arrhythmia resulting from inflammation following a mycoplasma infection.
One authority recently suggested that Thailand was preparing to declare its contracts for Pfizer vaccine “null and void” and go after the vaccine maker for damages.
Propagandists in the media have launched into overdrive to try to discredit such news and to claim “no evidence” of a vaccine tie to the sudden illness of the princess (without mentioning that there is no evidence exonerating the vaccine, either).
Google and other Big Tech companies, as well as their “fact-checkers” have repeatedly disseminated disinformation and censored accurate information on Covid and vaccines on behalf of vaccine industry interests.” (Sheryl Attikson)
“One daughter of the present king Rama X collapsed and is in a coma… within 23 days after the third shot, 44 years old, never been seriously ill, collapsed and is now in a coma.
The diagnosis that was given by the authorities and by the university is so ridiculous – she’s supposed to have a bacterial infection that will never do what she suffered from.
And so we are determined, and the activists in Thailand who have been on this many many months now – great guys, also a professor from the University of Bangkok, he’s gotten in touch with the Royal Family, and we are sending information to the Royal Family to alert them to the fact that in all probability the princess is suffering as a victim of this jab, as so many people around the world have been suffering.
Sucharit Bhakdi, fmr. professor of microbiology at University of Mainz, Germany
Is Pfizer in trouble with the Thai government over the Thai Princess' "vaccine injury"? 🧐
Top Thai officials are pulling off their gloves against Pfizer Bio N Tech and could become the first country in the world to Nullify the contracts between the government and Pfizer.
This would mean Pfizer would have to pay back billions of dollars because of their jabs to the Thai people.
Video
Comment by Prof. Michel Chossudovsky
Our thoughts are with Thailand’s Princess Bajrakitiyabha
A decision by Thailand to repeal its contractual relationship with Pfizer has to be carefully thought out. What we are dealing with on the part of Pfizer is a criminal endeavor applied Worldwide.
The Royal Thai Government should “nullify” its contracts with Pfizer while contemplating a formal criminal legal procedure against Pfizer, (which incidentally already has a criminal record for fraudulent marketing with the US Department of Justice) (2009).
We are no longer in the realm of “fraudulent marketing”.
The vaccine was launched in mid-December 2020.A Confidential Report by Pfizer released under Freedom of Information in October 2021, confirms unequivocally based on data recorded from mid-December 2020 to the end of February 2021 that the vaccine is a toxic substance resulting in mortality and morbidity.
The Report is now in the public domain. It should be consulted by the Royal Thai Government:
“Pfizer had already received more than 1,200 reports of deaths allegedly caused by the vaccine and tens of thousands of reported adverse events, including 23 cases of spontaneous abortions out of 270 pregnancies and more than 2,000 reports of cardiac disorders.”
The evidence is overwhelming. The data compiled from mid-December 2020 to the end of February 2021 unequivocally confirms “Manslaughter”. Based on that evidence, Pfizer had the responsibility to immediately cancel and withdraw the “vaccine”.
Pfizer’s Worldwide marketing of the Covid-19 Vaccine beyond February 28th, 2021, is no longer an “Act of Manslaughter”.
Murder as opposed to Manslaughter implies “Criminal Intent”.
Pfizer’s Covid 19 Vaccine constitutes a Criminal Act. From a legal standpoint, it is an “Act of Murder” applied Worldwide to a target population of 8 billion people. It’s a multibillion-dollar project.
What is contained in Pfizer’s “confidential” report is detailed evidence of the impacts of the “vaccine” on mortality and morbidity.
This data which emanates from the “Horse’s Mouth” can be used to confront as well as formulate criminal legal procedures against Pfizer.
We could end the debate on COVID vaccine safety instantly. All we need is the death-vax record data. But today, that data is being concealed by the health authorities in every jurisdiction. Here’s why
A simple database of death-vax records should be made publicly available by the CDC and other health authorities worldwide.
The death-vax records can be analyzed in seconds using a variety of totally objective methods to show whether the COVID vaccines have increased or decreased all-cause mortality in each age range.
No medical records, cause of death, etc. are required or needed. Just the age, date of death, and dates of vaccination are all that is required for each death since the start of the COVID vaccination program.
The death-vax data has been collected, but it has never been made publicly available anywhere in the world. There is no PII or HIPAA violation by disclosing the records.
There is absolutely no excuse for this data not to be made PUBLICLY available now.
Because kids are most at risk, universities in particular should be demanding data transparency of the death-vax records.
It is immoral and unethical for universities to mandate COVID vaccines if the health authorities refuse to show us the death-vax database records that would justify their use.
The death-vax record data
The death-vax data consists of one record for each death since Dec 14, 2020 to the present with these columns:
Age
Date of death
Date of each COVID vaccine administered (blank if unvaccinated)
The CDC could quickly collect this information, do the database join, remove the PII fields, and make this database publicly available.
This would reveal to the entire world whether the vaccines are safe or not. Instantly. No more debates.
No medical records are required. No judgment is required. The analysis is all based on mathematics and the law of large numbers. If the vaccines are saving lives, we’ll know it. If the vaccines are killing people, we’ll know it.
Introduction
EVERYONE should be demanding to see the death-vax record-level data. It can be easily compiled. It is dispositive. We’d know instantly whether the vaccines are safe or not. No more arguments. No more debates. No more censorship. One and done.
Yet, nobody in the mainstream infectious disease or epidemiology community seems to care about seeing this data. Nobody is calling for it. Why is that? Are they afraid of being proven they are wrong?
If the vaccine is so safe, they should be shouting for the release of this data from the rooftops because nearly 80% of the public is no longer drinking the Kool-Aid:
But the authorities are remaining silent and keeping the data under wraps. That can only mean one thing: the data is horrible and they know it. That’s why they are hiding it from public view.
That’s not just a hunch. I did my own data collection and analysis. Even after adjusting for the bias of the reporters (by restricting the analysis to just parents and grandparents of the reporter), the signal of harm was huge.
Science used to be about data. Not anymore.
Science used to be about data and what the data shows. Sadly, today, science is about what the CDC says, even if there is no data in support of the recommendation whatsoever.
The most stunning example of this is the “six-foot rule.” Did you know that it was entirely fabricated out of thin air? From Presidential Takedown page 49:
What is even more stunning is that the CDC has never admitted this publicly. This is evidence that they are a corrupt organization and the corruption goes to the very top of the organization.
We have over two years of data. Why not make it public?
We now have over two years’ worth of death and vaccination data for people who died after getting a COVID shot, yet nobody wants to see the record-level data tied to the vaccination dates?!?!
Let me be perfectly clear:
This is an abject failure of the entire medical community for not demanding to see this data.
People paid for us to see this data with their lives. Why is it being hidden from us?
In the US, hundreds of millions of people participated in a massive clinical trial and have data to share with people. At least 500,000 of the participants paid the ultimate price: they sacrificed their lives to send a message to America about the vaccines. It is extremely disrespectful to these people to ignore their death data and not share it with the public. Why are we not allowing these people to share their data?
Do you think if we could ask those people right before they died, “Do you want to let others know what killed you?” Do you think they would all say, “No! Don’t let anyone know. Please keep it a secret!”?
Every institution in the world that is recommending or requiring COVID vaccination should be DEMANDING to see this data made public
John Beaudoin and I have been calling for the death data to be set free and made public. We have been ignored.
Why aren’t any of these organizations calling for data transparency here so we can learn the truth?
The mainstream medical community
Heads of state throughout the world
The CDC
The FDA
The White House
Congress
The mainstream media
Public health authorities
Any doctor or nurse who recommends the jab to patients
Universities who mandate the vaccines for students, staff, or faculty
Any organization that supports COVID vaccines for their members, employees, or visitors
The data exists in VSD as well. But the CDC won’t allow anyone to see it.
The data exists in every state health department. But you can’t FOIA it because it requires a join to avoid PII problems and FOIA requests are not allowed if they generate effort like that. So FOIA requests won’t work.
It’s time for everyone to demand that our health authorities “Show us the data!”
We should all refuse to comply until they produce it.
In the same way Tom Cruise said passionately “Show me the money,” everyone all over the world should be equally passionate with their doctors and healthcare authorities and demand: “Show me the DATA” before we agree to comply with their requests/demands regarding vaccination.
Civil disobedience in Canada
Check out this video from True North entitled “Show us the data and evidence” that described the civil disobedience in Canada:
Business owners and local politicians are pushing back against the government’s lockdown measures. Their ask of the government is simple – if you’re going to shut us down, show us the data and evidence.
Calling all parents: ask your school why they aren’t calling for the data to be produced
The data that we have shows that the biggest harm is being done to kids.
Therefore, the biggest urgency is to put pressure on any school or university that recommends or requires the COVID vaccines to drop it immediately
Please ask the university president or head of school at any school your child attends to contact the CDC and let them know that if the CDC doesn’t make the death-vax record level data publicly available with the next 30 days, the school will suspend their COVID vaccination policies until such time as this data is produced and scientists can analyze it. That is the only ethical thing to do.
You can refer to my article in your email.
The public health authorities have been voluntarily keeping the data secret for two years now. That data would end the debate. We should not let them continue to get away with it.
All the excuses for not revealing this data are just that: excuses
I was just notified I will have the death-vax record data from one of the US states soon. It’s in progress.
If anyone thinks I’m bluffing, I’m happy to bet them $1M I’m not. Does anyone want to call me on that?
So if the other states in the US are not able to produce their data, we’ll all just have to rely on the data from this one state, won’t we?
Wow. Talk about an epic failure of 49 out of 50 states…
Poll
POLL
The CDC should make the death-vax records public
Agree
Disagree
No opinion
3335 VOTES · 4 DAYS REMAINING
Summary
It’s time for everyone to be demanding that the death-vax record data as described above be made public for everyone to see. There is absolutely no reason to keep this data hidden.
That data will tell us everything we need to know. It’s time to set the data free.
Show us the data. Show us the data. SHOW US THE DATA.
“I believed that the authorities responded to the largest public health crisis of our lives with compassion, diligence, and scientific expertise,” Bass writes. “I was wrong. We in the scientific community were wrong. And it cost lives.”
“I can see now that the scientific community from the CDC to the WHO to the FDA and their representatives, repeatedly overstated the evidence and misled the public about its own views and policies, including on natural vs. artificial immunity, school closures and disease transmission, aerosol spread, mask mandates, and vaccine effectiveness and safety, especially among the young. All of these were scientific mistakes at the time, not in hindsight. Amazingly, some of these obfuscations continue to the present day.”
A seventh-year student at a medical school in Texas penned an op-ed for Newsweek this week calling out the establishment for imposing lockdowns, masks, “vaccines” and booster shots, and other unscientific, life-destroying tyranny in the name of fighting covid.
Kevin Bass, a medical student and researcher, says he initially supported the government’s covid fascism. He believed it was the right thing to do in order to save lives, but now believes the exact opposite.
“I believed that the authorities responded to the largest public health crisis of our lives with compassion, diligence, and scientific expertise,” Bass writes. “I was wrong. We in the scientific community were wrong. And it cost lives.”
“I can see now that the scientific community from the CDC to the WHO to the FDA and their representatives, repeatedly overstated the evidence and misled the public about its own views and policies, including on natural vs. artificial immunity, school closures and disease transmission, aerosol spread, mask mandates, and vaccine effectiveness and safety, especially among the young. All of these were scientific mistakes at the time, not in hindsight. Amazingly, some of these obfuscations continue to the present day.”
Are the powers that be now openly admitting they were wrong to try to avoid paying the price for their crimes against humanity?
For whatever reason, Bass just believed everything that Tony Fauci and other authorities were declaring at the time as solutions to the covid virus, which to this day, just to clarify, has still never been isolated and proven to exist.
Now, though, Bass admits that the entire approach the scientific community took to address covid was “inherently flawed … and continues to be.” And these inherent flaws, he says, resulted “in thousands if not millions of preventable deaths.”
“What we did not properly appreciate is that preferences determine how scientific expertise is used, and that our preferences might be – indeed, our preferences were – very different from many of the people that we serve,” he explains.
“We created policy based on our preferences, then justified it using data. And then we portrayed those opposing our efforts as misguided, ignorant, selfish, and evil.”
Why this sudden change in belief? It could be because the entire world is waking up to the fact that the “vaccines” are a sham – and a deadly one, at that. Hundreds of millions of Americans let themselves get jabbed based on the inherently flawed consensus of the scientific community, of which Bass is a part.
These people’s inherently flawed beliefs at the start of the scamdemic destroyed so many lives that people are now demanding that heads roll. So, in an attempt to save themselves from the fallow, the Kevin Basses of the world are finally relenting to the fact that they were wrong in the hopes that the court of public opinion will deliver a non-guilty verdict and let their crimes against humanity slide.
Bass’s op-ed is shockingly admissive, and the fact that Newsweek even published it at all is telling. The narrative is shifting to where everyone, regardless of what “side” they are on, is reaching a common understanding that what happened during covid can never be allowed to happen again.
“My motivation for writing this is simple: It’s clear to me that for public trust to be restored in science, scientists should publicly discuss what went right and what went wrong during the pandemic, and where we could have done better,” Bass concludes.
“It’s OK to be wrong and admit where one was wrong and what one learned. That’s a central part of the way science works. Yet I fear that many are too entrenched in groupthink – and too afraid to publicly take responsibility – to do this.”
More covid-related news can be found at Plague.info.
“You maybe heard about Brooke Jackson’s case in the US. She’s suing Pfizer under False Claims Act that they defrauded the government. Well, Pfizer already filed a motion to dismiss – the case hasn’t been dismissed yet – but Pfizer already in court stated that: ‘Please dismiss this case, Judge. We did not defraud the government. We delivered the fraud that the government ordered.”
“[Pfizer] did not defraud the government. We delivered the fraud that the government ordered.” Sasha Latypova used these words to describe the basis on which Pfizer has requested the dismissal of a False Claims Act case brought against them for their covid “vaccines.”
The US Department of Defence ordered “demonstrations” from pharmaceutical companies using the same secretive framework they use to order weapons. While telling us they were pharmaceutical products, for legal reasons they described them as emergency use authorised “countermeasures.” No pharmaceutical regulation applies to countermeasures.
“They were claiming that they’re producing pharmaceutical products to the good manufacturing standards when they perfectly well knew, I assure you, they were all aware of this. They perfectly well knew that no pharmaceutical regulations apply to these things, countermeasures … They’re just lying to you that these are pharmaceuticals. They’re actually not,” Latypova explained.
The international conference ‘Pandemic Strategies: Lessons and Consequences’ held at the Stockholm Waterfront on 21-22 January 2023 gathered 15 leading doctors, researchers and lawyers from the US, Canada, UK, Germany, France, Belgium, Switzerland, Israel, Ukraine and Norway, along with 7 Swedes.
Presentations and panel discussions are being released in the order that they appeared on the program at a rate of 3 per day.
Alexandra “Sasha” Latypova was one of those who gave a presentation. She holds an MBA degree and is a former Pharmaceutical R&D Executive. Latypova has spent approximately 25 years in the pharmaceutical industry and has owned and managed several contract research organisations – conducting clinical trials for over 60 pharmaceutical clients worldwide. She became concerned about the irregularities, cover-up and apparent fraud relating to the extremely high number of deaths and injuries associated with the covid injection rollout.
In her presentation, she explained that her initial investigation was to look into the so-called covid vaccines’ compliance with good manufacturing practices. It is the practice required to conform to quality guidelines recommended by regulatory agencies and applies to drugs, food and other mass-produced products that are consumed. It is to ensure, for example, that if you buy your favourite beer today and then you go to the to buy it again a week from now or a month from now, your experience is the same. The same goes for medicines like Aspirin that you buy in a pharmacy. You don’t expect a product to be a thousand times different a week from now versus today.
“As a highly regulated industry, pharmaceutical manufacturers are supposed to comply with [good manufacturing practice]. And this means that the product that they claim that they make, with the ingredients that they claim that they make, is supposed to be in every vial, every shot, every pill, over and over and over again, and they should be almost identical to each other,” Latypova said.
In the first few months of her investigation, Latypova found evidence of “very bad manufacturing practices” in relation to the mRNA injections. “When I looked at the [ ] graph [of serious adverse events and deaths recorded in VAERS] for mRNA injections for the US, I found [the below]”
“[I’m] only looking at serious adverse events and deaths. There were almost no adverse events reported in some lots, and some lots had thousands and they had hundreds of deaths. And so, this is not a good manufacturing practice-compliant product at all,” said Latypova. “I’m not endorsing flu vaccines or any vaccines anymore, because until this is investigated fully, nobody should be taking anything. That’s my professional opinion.”
The above graph shows Johnson & Johnson (Janssen), Moderna and Pfizer. Below is a graph for Moderna. The blue colour represents serious adverse events and the orange represents death post-vaccination. “A well-manufactured product should not look like this at all,” Latypova explained.
Explaining the significance of the lot labelled in the graph above, Latypova said:
“On January 18, Orange County, California Health Department flagged this particular lot of Moderna for what they called ‘excessive number of allergic reactions’. Nothing was done about it. The injections were not stopped. In fact, this lot was being sold all over the United States until it ran out in late March.
“And as you know, if there is salmonella in a salad, they will recall the entire product from all the shelves in the country. Right? That’s what you should do as a manufacturer. All manufacturers have systems to detect this. And the majority of recalls of products are voluntary because they don’t want this to happen.
“Yet [with this lot from Moderna], nobody stopped. Not the manufacturer, not the health authorities of Orange County, not the CDC, FDA, or whoever was supposed to monitor this, they continued selling this lot. It’s now associated with over 65 deaths in the US and over 3000 serious adverse events. So, after something like this happens, everything that follows is intentional.”
Every researcher that has questioned or challenged regulatory authorities has been told: “We looked at it. It’s safe and effective. Go get vaccinated.” Why were they all behaving this way? Why are they all following the same script the world over?
Latypova has been collaborating with legal researcher Katherine Watt, who publishes articles on a Substack page titled ‘Bailiwick News’, to reveal the legal structure – or rather the pseudo-legal structure as it’s not lawful – of this government, pharma, military criminal cartel. “It actually is operating all over the world,” Latypova said.
In the 1960s a contracting framework was put into place for NASA called ‘Other Transaction Authority’. “Now eleven federal agencies use it. [The] Department of Defence is a particularly huge user of this contracting method because it allows them to contract without following any federal procurement rules and regulations with a lot of secrecy,” Latypova said. “They typically use this framework to order weapons from defence contractors, but now they’re using the same framework to order what they tell us is a pharmaceutical product.”
In addition to this, there is a US code, which Latypova highlights in her presentation, which says that the use of emergency use authorised “countermeasures” is not a clinical investigation under a public health emergency. The significance of this, Latypova explained, is that if a countermeasure cannot be a clinical investigational product, then no pharmaceutical regulation applies to these products.
“So, here’s the lie that our government told to us and told to the world and the governments all over the world repeated to their citizens:
“They were claiming that it’s a health event. They were claiming that they’re producing pharmaceutical products to the good manufacturing standards when they perfectly well knew, I assure you, they were all aware of this. They perfectly well knew that no pharmaceutical regulations apply to these things, countermeasures.
“They’re just lying to you that these are pharmaceuticals. They’re actually not … The government lied to us about this being a health event … [but] in reality, what they did, they organised the response to it as if it was war.”
Below is a slide from the presentation where the organisational structure of Operation Warp Speed was discussed. “The chief operating officer is the Department of Defence. We were told, ‘oh, they’re just doing logistics’. No, they’re not just doing logistics. They’re running the whole thing,” Latypova said.
As proof of this, Latypova cited the case where Pfizer or the FDA was refusing to release clinical trial data in less than 75 years.
“Who was arguing in court on behalf of Pfizer? Pfizer lawyers were not even in the room. It was the Department of Justice. So why is the US government defending presumably a private commercial interest of a pharmaceutical company?
“[In the slide above] you can see that the pharmaceutical companies are a third level down. They are not in charge, but they’re getting tremendous amounts of money to shut up and follow the orders and do as they’re told. [ ] The whole operation is run by the Department of Defence and the US government. I’m not absolving Pharma … of any responsibility. They are criminals in this cartel, and they’re collaborating, and they’re co-conspirators, and should be prosecuted together.”
In the same Operation Warp Speed presentation, Operation Warp Speed and BARDA were bragging about their vaccine manufacturing portfolio. On the right-hand side, they call it vaccine-supporting efforts. “These are all established defence contractors … who already had an established vaccine manufacturing base. At that time, it was called pan influenza. In early 2020, they simply switched to covid,” Latypova said. “These are the companies who are really making these products.”
“On [the left-hand] side, it’s called ‘Demo’. That’s what the government ordered, a demonstration, which is fake by definition … These words are very carefully designed. They have legal meaning, and that’s exactly what they bought. They bought demonstrations.”
They spent $47 billion on research and development contracts – $33 billion was spent on “vaccines.” All the contracts are publicly available HERE. All of them say the Department of Defence contracted these companies. And they’re managed through Advanced Technologies International, a long-standing contracts manager for the Department of Defence.
They exempt everyone who participates in this, regardless of where they’re working, as long as they’re following the orders, they’re exempt from liability under the Prep Act clause. That same Prep Act clause states that this is a dual-use civil and military application product. How they exempted themselves internationally is by Pfizer forcing countries to sign predatory contract clauses where the national governments had to lift good manufacturing practice requirements or any drug importation requirements and look the other way. Clauses that if, for example, Swedish citizens get injured and sue Pfizer, then the Swedish government has to indemnify Pfizer and put state assets such as military bases, embassies, and other state assets as collateral. “That’s because it’s the US government who wants that base, not the private commercial manufacturer,” Latypova explained.
“You maybe heard about Brooke Jackson’s case in the US. She’s suing Pfizer under False Claims Act that they defrauded the government. Well, Pfizer already filed a motion to dismiss – the case hasn’t been dismissed yet – but Pfizer already in court stated that: ‘Please dismiss this case, Judge. We did not defraud the government. We delivered the fraud that the government ordered.”
Over One Thousand Scientific Studies Prove That the COVID-19 Vaccines Are Dangerous, and All Those Pushing This Agenda Are Committing the Indictable Crime of Gross Misconduct in Public Office
Just over 12 months from deployment of the COVID 19 emergency use experimental vaccines, scientific studies in the thousands, and reports of criminal complaints of assault and murder from the illegal, unlawful use of biochemical poisons made to police forces around the country, verify an assault on an unsuspecting UK population. Irrefutable science shows that the COVID 19 vaccine is not safe and not effective in limiting transmission or infection from the SARS-CoV-2, coronavirus pathogens.
The “safe and effective” false propaganda, put out by public officials who now are continuing to push this vaccine, is a clear breach of duty. A public office holder is subject to, and aware of, a duty to prevent death or serious injury that arises only by virtue of the functions of the public office.
Many have breached that duty and, in doing so, are recklessly causing a risk of death or serious injury, by carrying on regardless of the now-confirmed dangers associated with COVID 19 injections. Some of these risks are blood clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia, anaphylaxis, Bell’s palsy, Guillain-Barre, cancer including deaths, etc.
All of these are confirmed in the following science-and-government-gathered data from the UK Health and Security agency on COVID 19 regarding vaccine damage.
The term “vaccine” was changed recently to incorporate this illegal, unlawful medical experiment to facilitate usage of mRNA technology that is demonstrably not a vaccine, and which contains biologically toxic nano-metamaterials associated with 5G urban data gathering capability.
Metal nanoparticulates are known in science to be genotoxic—a poison that can also cause sterilization. The dangers posed to the victims in the near term from this medical battery are now known. However, the long term lethality of this weapon is not as yet realized due to the debilitating effects it has on the immune system, causing Acquired Immunodeficiency Syndrome(AIDS).
The Medicines and Healthcare (products) Regulatory Agency (MHRA) had prior warning of the expected large numbers of adverse reactions before the deployment—confirming the premeditated nature of the crime and public conduct offences then and now.
US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: https://pubmed.ncbi.nlm.nih.gov/33929487/
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046
Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: https://pubmed.ncbi.nlm.nih.gov/34219532/
Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: https://pubmed.ncbi.nlm.nih.gov/34333695/
Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. https://www.sciencedirect.com/science/article/pii/S1871402121002046.
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: https://pubmed.ncbi.nlm.nih.gov/33444297/
Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: https://pubmed.ncbi.nlm.nih.gov/33507892/
Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/
Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: https://pubmed.ncbi.nlm.nih.gov/34347278/
Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: https://pubmed.ncbi.nlm.nih.gov/33657648/
Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: https://pubmed.ncbi.nlm.nih.gov/33919151/
Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: https://pubmed.ncbi.nlm.nih.gov/33752263/
Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: https://pubmed.ncbi.nlm.nih.gov/34487581/
Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: https://pubmed.ncbi.nlm.nih.gov/33987882/
Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https://pubmed.ncbi.nlm.nih.gov/34446426/
Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: https://pubmed.ncbi.nlm.nih.gov/34365148/.
Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/34452064/.
A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33917902/
Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://pubmed.ncbi.nlm.nih.gov/34256983/
Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/
59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34117206/
Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: https://pubmed.ncbi.nlm.nih.gov/34033927/
Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34453510/
Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34369471/
Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: https://pubmed.ncbi.nlm.nih.gov/34139321/.
Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: https://pubmed.ncbi.nlm.nih.gov/34293683/.
Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/33864750/
Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33914590/
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https://pubmed.ncbi.nlm.nih.gov/34446426/
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: https://pubmed.ncbi.nlm.nih.gov/34261633/.
central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34191218/
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/.
Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34144250/
Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34011137/.
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/.
Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: https://pubmed.ncbi.nlm.nih.gov/34083026/.
Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: https://pubmed.ncbi.nlm.nih.gov/34375510/
Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34355379/.
fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https://pubmed.ncbi.nlm.nih.gov/34416319/.
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34291477/
Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34474550/
Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: https://pubmed.ncbi.nlm.nih.gov/34015240/
Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: https://pubmed.ncbi.nlm.nih.gov/34516272/.
Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: https://pubmed.ncbi.nlm.nih.gov/34512961/
Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: https://pubmed.ncbi.nlm.nih.gov/34350668/
COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: https://pubmed.ncbi.nlm.nih.gov/34509271/.
Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34462996/
COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: https://pubmed.ncbi.nlm.nih.gov/34435142/
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/.
Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: https://pubmed.ncbi.nlm.nih.gov/34286453/.
Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34226070/
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/.
Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: https://pubmed.ncbi.nlm.nih.gov/34313952/
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/
S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: https://pubmed.ncbi.nlm.nih.gov/33929487/.
Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/.
Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34490632/
An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33909350/
Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: https://pubmed.ncbi.nlm.nih.gov/33981305/.
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/33877737/
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/.
Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34276917/
Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33990339/.
Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: https://pubmed.ncbi.nlm.nih.gov/34314875/.
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: https://pubmed.ncbi.nlm.nih.gov/34382387/
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI
A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: https://pubmed.ncbi.nlm.nih.gov/34601006/
This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: https://pubmed.ncbi.nlm.nih.gov/34626338/
Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/
Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34598301/
Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: https://pubmed.ncbi.nlm.nih.gov/34696248/
Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: https://pubmed.ncbi.nlm.nih.gov/34782400/
Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34710832/
Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: https://pubmed.ncbi.nlm.nih.gov/34624910/
Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34580132/.
A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: https://pubmed.ncbi.nlm.nih.gov/34535492/
Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: https://pubmed.ncbi.nlm.nih.gov/34706921/
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33877737/
Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34646685/
Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https://pubmed.ncbi.nlm.nih.gov/34006408/
Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: https://pubmed.ncbi.nlm.nih.gov/34664303/.
Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: https://pubmed.ncbi.nlm.nih.gov/34819146/.
Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: https://pubmed.ncbi.nlm.nih.gov/34755433/
Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: https://pubmed.ncbi.nlm.nih.gov/34667486/
Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: https://pubmed.ncbi.nlm.nih.gov/34726187/.
Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: https://pubmed.ncbi.nlm.nih.gov/34661934/
Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34788138
A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: https://pubmed.ncbi.nlm.nih.gov/34769454/
Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: https://pubmed.ncbi.nlm.nih.gov/34833382/
Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): https://pubmed.ncbi.nlm.nih.gov/34670287/
Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: https://pubmed.ncbi.nlm.nih.gov/34023956/.
Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34630307/
Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: https://pubmed.ncbi.nlm.nih.gov/34579248/
A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: https://pubmed.ncbi.nlm.nih.gov/34843991/
Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: https://pubmed.ncbi.nlm.nih.gov/34639132/
Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: https://pubmed.ncbi.nlm.nih.gov/34804412/
Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https://pubmed.ncbi.nlm.nih.gov/34402230/
Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/.
Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: https://pubmed.ncbi.nlm.nih.gov/34219532/
Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https://pubmed.ncbi.nlm.nih.gov/34402230/
COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: https://pubmed.ncbi.nlm.nih.gov/34632750/
Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: https://pubmed.ncbi.nlm.nih.gov/34887867/.
Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34880826/
Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34097311/
Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: https://pubmed.ncbi.nlm.nih.gov/34820232/.
Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258
Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: https://pubmed.ncbi.nlm.nih.gov/34790684/
Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: https://pubmed.ncbi.nlm.nih.gov/34096082/
Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34496880/
Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: https://pubmed.ncbi.nlm.nih.gov/34664804/
Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: https://pubmed.ncbi.nlm.nih.gov/34166671/
Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: https://pubmed.ncbi.nlm.nih.gov/34333695/.
Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/
Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34848416/
Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/
Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/34796417/.
A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): https://pubmed.ncbi.nlm.nih.gov/34871447/
Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: https://pubmed.ncbi.nlm.nih.gov/34810163/
Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/
Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34660149/
Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/
A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: https://pubmed.ncbi.nlm.nih.gov/34635376/
Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34848426/.
Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34859017/
Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: https://pubmed.ncbi.nlm.nih.gov/34411532/
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: https://pubmed.ncbi.nlm.nih.gov/33641264/
Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: https://pubmed.ncbi.nlm.nih.gov/33641268/
Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34579211/
Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: https://pubmed.ncbi.nlm.nih.gov/34343674/
Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: https://pubmed.ncbi.nlm.nih.gov/34807248/
A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: https://pubmed.ncbi.nlm.nih.gov/34703815/
Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34659268/
Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34510694/
Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: https://pubmed.ncbi.nlm.nih.gov/33774684/
Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/
Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: https://pubmed.ncbi.nlm.nih.gov/34115709/.
Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: https://pubmed.ncbi.nlm.nih.gov/34731748/
Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https://pubmed.ncbi.nlm.nih.gov/34526175/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https://pubmed.ncbi.nlm.nih.gov/34526175/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. https://www.ncbi.nlm.nih.gov/pubmed/34416319
Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/pubmed/34092429
Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885
Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408
Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. https://www.ncbi.nlm.nih.gov/pubmed/34756746
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. https://www.ncbi.nlm.nih.gov/pubmed/34432976
Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. https://www.ncbi.nlm.nih.gov/pubmed/34754400
Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. https://www.ncbi.nlm.nih.gov/pubmed/34281357
Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284
Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. https://www.ncbi.nlm.nih.gov/pubmed/34366403
Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344
Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. https://www.ncbi.nlm.nih.gov/pubmed/34617315
Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. https://www.ncbi.nlm.nih.gov/pubmed/34333695
Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. https://www.ncbi.nlm.nih.gov/pubmed/34833382
Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. https://www.ncbi.nlm.nih.gov/pubmed/34704459
Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. https://www.ncbi.nlm.nih.gov/pubmed/34664804
Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. https://www.ncbi.nlm.nih.gov/pubmed/34860360
Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657
Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/34933012
Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. https://www.ncbi.nlm.nih.gov/pubmed/34547487
Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. https://www.ncbi.nlm.nih.gov/pubmed/34339728
Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/pubmed/34356586
Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. https://www.ncbi.nlm.nih.gov/pubmed/34219532
Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. https://www.ncbi.nlm.nih.gov/pubmed/34246585
Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161
Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. https://www.ncbi.nlm.nih.gov/pubmed/34844930
Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. https://www.ncbi.nlm.nih.gov/pubmed/34487236
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. https://www.ncbi.nlm.nih.gov/pubmed/34551225
Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/34709227
Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. https://www.ncbi.nlm.nih.gov/pubmed/34921468
Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. https://www.ncbi.nlm.nih.gov/pubmed/34824230
Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. https://www.ncbi.nlm.nih.gov/pubmed/34170372
Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667
Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. https://www.ncbi.nlm.nih.gov/pubmed/34646267
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. https://www.ncbi.nlm.nih.gov/pubmed/34127481
Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. https://www.ncbi.nlm.nih.gov/pubmed/34538306
Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/34237049
Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694
Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088
Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517
Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. https://www.ncbi.nlm.nih.gov/pubmed/34668687
Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. https://www.ncbi.nlm.nih.gov/pubmed/34348657
Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. https://www.ncbi.nlm.nih.gov/pubmed/34351881
Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395
Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/pubmed/34446426
Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/pubmed/34808708
Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. https://www.ncbi.nlm.nih.gov/pubmed/34347278
Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755
Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. https://www.ncbi.nlm.nih.gov/pubmed/34931681
Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. https://www.ncbi.nlm.nih.gov/pubmed/34342500
Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376
Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. https://www.ncbi.nlm.nih.gov/pubmed/34834983
Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. https://www.ncbi.nlm.nih.gov/pubmed/34389692
Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. https://www.ncbi.nlm.nih.gov/pubmed/34270752
Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/pubmed/34744118
Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/34568540
Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. https://www.ncbi.nlm.nih.gov/pubmed/34447639
Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046
Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. https://www.ncbi.nlm.nih.gov/pubmed/34402228
King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358
Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. https://www.ncbi.nlm.nih.gov/pubmed/34477808
Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. https://www.ncbi.nlm.nih.gov/pubmed/33898162
Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. https://www.ncbi.nlm.nih.gov/pubmed/33643776
Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. https://www.ncbi.nlm.nih.gov/pubmed/34952008
Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. https://www.ncbi.nlm.nih.gov/pubmed/34642628
Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. https://www.ncbi.nlm.nih.gov/pubmed/34540594
Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. https://www.ncbi.nlm.nih.gov/pubmed/34378087
Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. https://www.ncbi.nlm.nih.gov/pubmed/34127854
Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/pubmed/34393110
Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. https://www.ncbi.nlm.nih.gov/pubmed/34463770
Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. https://www.ncbi.nlm.nih.gov/pubmed/33606296
Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. https://www.ncbi.nlm.nih.gov/pubmed/34535317
Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. https://www.ncbi.nlm.nih.gov/pubmed/33888900
Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/34834458
Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411
Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057. https://www.ncbi.nlm.nih.gov/pubmed/34332972
Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001. https://www.ncbi.nlm.nih.gov/pubmed/34375696
Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. doi:10.1093/cid/ciab954. https://www.ncbi.nlm.nih.gov/pubmed/34791081
Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131. doi:10.1155/2021/6901131. https://www.ncbi.nlm.nih.gov/pubmed/34676123
Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295. doi:10.1002/pbc.29295. https://www.ncbi.nlm.nih.gov/pubmed/34398511
Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study. Public Health, 190, 4-6. doi:10.1016/j.puhe.2020.11.005. https://www.ncbi.nlm.nih.gov/pubmed/33316478
McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/34133825
Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. https://www.ncbi.nlm.nih.gov/pubmed/34614328
Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. https://www.ncbi.nlm.nih.gov/pubmed/34166671
Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun, 12(1), 6379. doi:10.1038/s41467-021-26672-3. https://www.ncbi.nlm.nih.gov/pubmed/34737312
Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-20. https://www.ncbi.nlm.nih.gov/pubmed/33526560
Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-06949-0. https://www.ncbi.nlm.nih.gov/pubmed/34930152
Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045
Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. https://www.ncbi.nlm.nih.gov/pubmed/34840235
Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006. https://www.ncbi.nlm.nih.gov/pubmed/34876937
Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765. doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859
Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/34889875
Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-4. https://www.ncbi.nlm.nih.gov/pubmed/34320609
Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232. https://www.ncbi.nlm.nih.gov/pubmed/34402230
Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390
Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4. https://www.ncbi.nlm.nih.gov/pubmed/34496880
Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-0. https://www.ncbi.nlm.nih.gov/pubmed/34907393
Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386
Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093/cid/ciab926. https://www.ncbi.nlm.nih.gov/pubmed/34734240
Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9. https://www.ncbi.nlm.nih.gov/pubmed/34738774
Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42. doi:10.1002/ajh.26385. https://www.ncbi.nlm.nih.gov/pubmed/34695229
Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34. doi:10.1016/j.ejca.2021.06.002. https://www.ncbi.nlm.nih.gov/pubmed/34233234
Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252. doi:10.1148/ryct.210252. https://www.ncbi.nlm.nih.gov/pubmed/34934954
Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083. https://www.ncbi.nlm.nih.gov/pubmed/34228985
Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9. https://www.ncbi.nlm.nih.gov/pubmed/34591186
Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5. https://www.ncbi.nlm.nih.gov/pubmed/34241676
Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390/jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172
Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389/fimmu.2021.714170. https://www.ncbi.nlm.nih.gov/pubmed/34707602
Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. https://www.ncbi.nlm.nih.gov/pubmed/33956784
Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383. doi:10.7759/cureus.16383. https://www.ncbi.nlm.nih.gov/pubmed/34408937
Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230. https://www.ncbi.nlm.nih.gov/pubmed/34739045
Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/34605853
Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797
Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-1. https://www.ncbi.nlm.nih.gov/pubmed/34764489
Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/34077949
Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. doi:10.1016/j.healun.2021.11.001. https://www.ncbi.nlm.nih.gov/pubmed/34911654
Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430. https://www.ncbi.nlm.nih.gov/pubmed/34282971
Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869
Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319. https://www.ncbi.nlm.nih.gov/pubmed/34514306
Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935. https://www.ncbi.nlm.nih.gov/pubmed/34955479
Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. https://www.ncbi.nlm.nih.gov/pubmed/33444297
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329. doi:10.1056/NEJMoa2107058. https://www.ncbi.nlm.nih.gov/pubmed/34192428
Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634. https://www.ncbi.nlm.nih.gov/pubmed/34866957
Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. Circulation. doi:10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/34865500
Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926. https://www.ncbi.nlm.nih.gov/pubmed/34311983
Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/pubmed/34904134
Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759/cureus.15576. https://www.ncbi.nlm.nih.gov/pubmed/34277198
Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi:10.1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/34731877
Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/34533570
Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940
Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health, 9, 695807. doi:10.3389/fpubh.2021.695807. https://www.ncbi.nlm.nih.gov/pubmed/34336774
Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054. https://www.ncbi.nlm.nih.gov/pubmed/34006408
Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737. https://www.ncbi.nlm.nih.gov/pubmed/34614329
Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-320338. https://www.ncbi.nlm.nih.gov/pubmed/33262177
Truly, they have a wondrous capacity to invert reality.
But, for all the revisionism, fascism as a governing ideology actually means something very specific.
Progenitor of the ideology, Italian fascist dictator Benito Mussolini, infamously defined fascism – or, alternatively, corporatism — as the “merger of corporate and state power.”
Let’s examine true 21st-century techno-fascism, and how it works in the real world:
A full quarter of the nation’s economic activity is allocated to projects carried out theoretically in the public interest, funded by the public treasury.
As one might expect from the massive bureaucratic infrastructure necessary to administer this activity, these vast resources are frequently abused. On an opaque journey through a series of unseen hands, the funds are redirected into private purses with limited or no benefit to the actual public. Private interests suckling at the teat of power are the biggest beneficiaries.
The most obvious example of the fascist grift in the modern era is the mRNA COVID “vaccines.”
The private, for-profit pharmaceutical industry has long abused the public coffers by bribing politicians through campaign donations, who in turn funnel taxpayer money into the subsidy of private “research and development” (called “R&D” in the industry). The COVID-19 pandemic greatly expanded the scope of public funding of the pharmaceutical industry’s projects.
“There also has been a major shift in the funding of product commercialization during the pandemic. Government agencies and philanthropic organizations are offering large sums not only to support research but to fund late-stage product development, the expansion of manufacturing capacity, and efficient systems for distribution. In the past, these activities have been funded largely by the pharmaceutical industry.”
Pfizer and Moderna pillage the treasury to offset the cost of research and development for their mRNA shots. Then, once they’re developed, they manage to get the government to cover the price for the shots administered to the public.
The shot is then marketed as “free” to the public. But, of course, the public is paying for the shots via the treasury. The problem is that no one sees dollars drained from their personal bank accounts. The cost to the individual, which is filtered through large institutions, seems far-off. To Joe Six-Pack and Sally PTA, they’re just vague digits in some government spreadsheet.
Meanwhile, Pfizer and Moderna reap record profits because their project costs are subsidized on the back end and they get a premium at the point of sale. Pfizer doubled its profits from 2020 to 2021 by selling its COVID shots to the government that paid to develop them in the first place.
Project Veritas recently exposed an undercover meeting with a Pfizer executive in which he admitted that “Pfizer is a revolving door for all government officials.”
He flat out states that individual FDA officials go easy on Pfizer, knowing that they will later receive an extremely lucrative job or consulting gig from Pfizer.
Then you have the actual mandate to use the product. You will enrich Pfizer, or the government will use its power of force to make you lose your job.
This fits perfectly the actual definition of fascism.
In the end, the public treasury is bankrupted and the national debt soars, while no one seemingly cares – certainly not the industries that profit of the public dole.
Of course, the pharmaceutical industry is just one head of the private-public hydra.
There is also, for example, the sports industry that manipulates local governments into funding bloated stadiums with empty promises of a return on investment at some future point.
The Pentagon, for instance, has never once passed an audit. Were it a private entity, with a fiduciary responsibility to stakeholders, its administrators would be on the hook for civil and potentially even criminal penalties for malfeasance. Instead, its incompetent management is rewarded with year-on-year budget increases.
It’s bad enough to be forced to support businesses we don’t want to.
But it reaches another whole level when the fascists force us to inject their product into our bodies, or when they force us into their for-profit wars.
Ben Bartee is an independent Bangkok-based American journalist with opposable thumbs. Follow his stuff via Armageddon Prose and/or Substack, Patreon, Gab, and Twitter.
Between 2014 and 2019, US tax dollars were funnelled to the Wuhan Institute of Virology via EcoHealth Alliance. Given that US scientists have far more virology expertise than the Chinese, this begs an obvious question: what type of research was US tax dollars paying for in Wuhan, China? Dr. Fauci’s surprising statement in an interview might provide the short answer to this question: “You don’t want to go to Hoboken, NJ or Fairfax, VA to be studying the bat-human interface that might lead to an outbreak, so you go to China.”
Given what we’ve endured for the past three years, Fauci’s “so you go to China” comment suggests that he hadn’t considered the global implications of a highly transmissible coronavirus leaking from a Chinese lab plagued by serious safety issues.
Unwilling to admit that he, EcoHealth Alliance, and their Chinese collaborators, are suspects in one of the largest crimes against humanity, Fauci instead opted to conspire with his boss, Francis Collins, to declare “lab leak” a “destructive conspiracy” that must be “put down.” Sadly, it’s clear that from the beginning, these two distinguished scientists made up their minds about the virus’s origin without evidence from both sides of the debate.
Even worse, renowned scientists that rely on Fauci for their research funding, fearful of sanctions being placed on their life’s work, rallied around the “anti-lab leak” stance. One of the premier scientific journals, Science, whose political bias has become very apparent, attempted to provide legitimacy to Fauci’s position by publishing a paper by authors that claimed “dispositive evidence” that SARS-CoV-2 emerged from an animal at the Wuhan market. This paper allegedly “crushed” the lab-leak hypothesis, despite leaving much room for debate.
The good news is that Big Tech, scientific journals, and most media sources were forced to stop censoring countervailing evidence as it reached critical mass and began spilling over into the public domain. Far from being a “conspiracy,” there is a lot of evidence that strongly suggests SARS-CoV-2 is an engineered virus that spread from a Wuhan virology lab. Before getting into the evidence that SARS-CoV-2 was engineered and leaked from a lab, let’s start a debate around the “dispositive evidence” that SARS-CoV-2 is natural and emerged from the Wuhan market.
The “market origin hypothesis” is based on four debatable premises
The entirety of the “dispositive evidence” for market origin cited by Dr. Fauci and others can be summed up as follows: 1) “Early” cases allegedly lived near the market, 2) “early” SARS-CoV-2 lineages were allegedly associated with the market, 3) wild animals susceptible to COVID-19 were sold at the market, and 4) positive SARS-CoV-2 samples were found in the environment around the market and were allegedly “linked to human cases.” For many reasons, some of which are discussed here, none of this evidence is anywhere near “dispositive.” This is why reviewers forced the authors to remove the phrase “dispositive evidence” as a requirement for publication.
Did “early cases” really live near the market?
The Science paper relied on a joint World Health Organization (WHO)-China report to define “early cases” as those that occurred in December 2019. However, the joint WHO-China report also states: “Based on molecular sequence data, the results suggested that the outbreak may have started sometime in the months before the middle of December 2019.”
This statement seems more in line with other evidence that the pandemic started earlier than December 2019. Urgent communications from the highest levels of the Chinese government circulating at the Wuhan Institute of Virology in November 2019 reported a “complex and grave situation” at the lab. Was this “grave situation” the start of a SARS-CoV-2 “lab leak” unfolding in real-time, weeks before the rest of the world was made aware of the imminent pandemic?
There were also multiple reports from Chinese media and even the venerable Lancet that documented initial cases started before December 2019, as well as lab-based evidence of international spread as early as November 2019. Furthermore, shouldn’t we be alarmed that a group led by Chinese military scientists applied for a COVID-19 vaccine patent in February 2020?
If the first COVID-19 cases really were in December 2019, this means that inexperienced Chinese military researchers somehow managed to produce a COVID-19 vaccine based on traditional, less efficient methodology, in a little over a month. For comparison, it took vaccine giant Pfizer about 9 months to produce their vaccine based on a more efficient mRNA methodology. Accurately pinpointing the true start date of the pandemic would allow us to assess how meaningful the “early cases” data are. If countervailing evidence is correct and cases that preceded December 2019 were missed or ignored, then a dataset beginning in December would most likely lead to flawed conclusions about the pandemic origin.
Were “early virus lineages” really associated with the market?
In perhaps the clearest evidence of a crime scene coverup, Chinese scientists quietly removed from public databases at least 13 genome sequences representing the earliest SARS-CoV-2 strains. There is no legitimate reason for doing that. Fortunately, the files had been backed up before they were removed, allowing Dr. Jesse Bloom to be the first to retrieve them from Google Cloud and analyze them.
This is proof that the Science paper many claimed to have “crushed” the lab leak was unlikely to be fully representative of the viruses spreading at the start of the pandemic. Adding to the intrigue, one of the authors of the Science paper attempted to intimidate Dr. Bloom so he would not publish his findings. If the evidence for a natural origin of SARS-CoV-2 is so “dispositive,” why would anyone feel the need to censor an expert like Dr. Bloom?
Animals susceptible to COVID-19 were sold at the market but none tested positive.
Some of the animals trafficked at the market had been experimentally infected with SARS-CoV-2 in labs or deemed theoretically susceptible based on the presence of compatible receptors. However, the WHO-China Report revealed that none of the 457 samples taken from 188 animals at the market tested positive for SARS-CoV-2. A criticism of these negative results is that the market was “under-sampled.” The SARS-CoV-1 pandemic of 2003-2004 spread around the world causing about 8,000 documented infections, resulting in about 800 deaths. Chinese scientists mobilized immediately and within a few months discovered an identical virus that naturally occurs in palm civet cats that were sold in Chinese markets.
Yet here we are, three years later, thousands of additional animals have been sampled, millions of genomic sequences analyzed, and nothing close to SARS-CoV-2 has yet to be detected in nature. Why is that?
Positive environmental samples found at the market were taken too late to infer virus origin
SARS-CoV-2-positive environmental samples were detected at the market. However, the samples were taken between January and March 2020. By January, the virus had likely been spreading in Wuhan for more than a month, and had already spread internationally, so how much can we deduce from these samples taken from the heavily trafficked market, weeks after the pandemic started? In fact, those responsible for collecting the samples concluded, “Tthe market might have acted as an amplifier due to the high number of visitors every day.”
In other words, infected people most likely entered the crowded market and spread the virus. It’s notable that many of the positive samples came from vendor stalls in which “aquatic products,” seafood, and vegetables were sold. None of these products could be a natural reservoir for SARS-CoV-2. In fact, the WHO-China report concludes that many of the environmental samples reflect “contamination from cases” (i.e., infected people) given how widely distributed the virus was by then.
The following is a review of some of the lab-based and circumstantial evidence supporting the “lab leak.” Hopefully, this analysis will lay the foundation for honest, thoughtful discussion, leading to a true understanding of the origin of SARS-CoV-2. If we can’t have honesty, how will we ever minimize the chances of this happening again?
Early strains of SARS-CoV-2 were unnaturally human adapted
The “natural origin” hypothesis contends that SARS-CoV-2 spilled over into humans from an animal in December 2019. A virus that so recently jumped to humans from an animal should not bind to human cells with higher affinity than the animal host it came from. However, at the beginning of the pandemic, Dr. Nikolai Petrovsky’s lab made the startling discovery that the earliest known strains of SARS-CoV-2 were unnaturally human-adapted.
In fact, these strains showed the highest affinity for human cell receptors over receptors from bats, pangolins, and about eleven other animals known to harbor coronaviruses. Dr. Petrovsky submitted this important research to a top journal, Nature,in August 2020. In an egregious example of censorship, Nature delayed publishing the paper until June 2021, corresponding to when Dr. Fauci finally admitted that a lab leak could have started the pandemic.
There was financial motivation and established methodology for creating pandemic viruses
A rejected 2018 grant proposal submitted to DARPA that includes EcoHealth Alliance and Wuhan Institute of Virology (WIV) collaborators gives us enough information to figure out the motivation and methodology that likely created SARS-CoV-2. The primary goal of the grant was to create a “complete inventory” of SARS-like coronaviruses taken from several bat caves in China.
What follows is a streamlined version of the workflow proposed by the researchers: 1) add the spike proteins from these novel bat coronaviruses to a previously characterized SARS-like bat coronavirus core, and insert genetic modifications to spike proteins for enhanced infectivity if necessary, 2) infect “humanized” mice with these lab-made viruses, 3) flag chimeric viruses capable of infecting the mice as potential pandemic strains, and 4) prepare “spike” protein vaccines from these potential pandemic strains and use them to “immunize” bats in caves (Fig. 1).
Fig. 1. Risky research methodology used by EcoHealth Alliance, WIV, and their collaborators to attempt to create bat vaccines. There’s no way of knowing in advance the pandemic potential of unnatural, chimeric SARS-like viruses created in this workflow.
The authors of the DARPA proposal discuss the importance of spike protein cleavage by human enzymes such as furin in the ability of coronaviruses to spread optimally and become pandemic strains. Notably, they proposed to insert “human-specific cleavage sites” (e.g., furin cleavage site, FCS) in spike proteins that lack the functional cleavage sites and then “evaluate the growth potential” of the modified viruses in human cells.
They further proposed to modify cleavage sites in highly abundant, low-risk SARS-like viruses taken from Chinese bat caves. These studies are precisely the type of work that could accidentally or intentionally create pandemic viruses. Although the proposal states that chimeric virus work would be done at the University of North Carolina, by Fauci’s own admission, “I can’t guarantee everything that’s going on in the Wuhan lab, we can’t do that.” Furthermore, whenever a proposal this large (i.e., a $14 million request) is submitted, a great deal of the work will have already been done in advance to provide the “proof of concept” needed to sway reviewers.
The unique furin cleavage site in SARS-CoV-2 is evidence of genetic engineering
Many natural coronaviruses contain an FCS, so why is an FCS in SARS-CoV-2 so suspicious? The answer is that the genomes of thousands of coronaviruses from hundreds of different animals have been sequenced, and it’s clear that only distant relatives of SARS-CoV-2 have an FCS (see Fig 1A, Table 1).
The closest known sibling of SARS-CoV-2, a bat coronavirus named RaTG13, at best weakly infects human cells and lacks an FCS. SARS-CoV is another sibling of SARS-CoV-2, and like all the other known siblings, also lacks an FCS. Without an FCS, SARS-CoV-1 spread around the world in 2003-2004 but fizzled out after infecting about 8,000 people. A comparison of the short stretch of amino acids in the spike protein clearly reveals the missing FCS in these SARS-CoV-2 siblings (Fig. 2).
Fig. 2. Comparison of partial spike protein amino acids showing the FCS of SARS-CoV-2 (i.e., “PRRAR”), and the lack of FCS in two of its siblings. Different letters represent unique amino acids. Identical amino acids in all three viruses are highlighted in yellow; dashed lines indicate the missing FCS.
The unique genetic code of the SARS-CoV-2 furin cleavage site is evidence of genetic engineering
In coronaviruses, the blueprint for assembling proteins such as the surface spikes needed for infection lies in their RNA genome. The specific genomic sequence that encodes the short, all-important FCS within the SARS-CoV-2 spike is: CCU CGG CGG GCA CGU. Each three-letter bit of code (i.e., codon) dictates the specific amino acid to be used in building the FCS. Thus, CCU encodes “P” (for proline), CGG encodes “R” (for arginine), GCA encodes “A” (for alanine), and CGU also encodes “R.”
As you can see, there is redundancy in the genetic code (e.g., there are six different codons that a virus can use to encode arginine). The odd feature of the SARS-CoV-2 FCS is the double CGG codons. In fact, CGG is one of the rarest codons in human coronaviruses, yet there just so happens to be two right next to each other in the FCS, one of the most important sequences in the entire 29,903 “letters” making up the SARS-CoV-2 genome.
In fact, these are the only two CGG codons out of the 3,822 “letters” encoding the SARS-CoV-2 spike protein, and they are the only instance of a CGG-CGG doublet in any of the closest relatives of SARS-CoV-2. Notably, an arginine-rich FCS enhances the ability of coronaviruses to infect cells. At this point, it should not surprise anyone that CGG codons are the preferred code for genetic engineers who wish to produce an arginine-containing protein in human cells. It’s hard to deny that the CGG-CGG in the SARS-CoV-2 FCS is a “smoking gun”-level evidence of genetic tampering.
Suspicious cut sites in the SARS-CoV-2 genome are evidence of genetic engineering
One method to create chimeric viruses utilizes specialized genome-cutting enzymes called “Endonucleases.” Endonucleases can be used to cut virus genomes in specific places, then the pieces can be strategically recombined to create chimeric viruses. Cut sites are randomly distributed in the genomes of natural viruses, but they can be precisely inserted or removed by scientists to make chimeric viruses in a laboratory. BsmBI and BsaI are two examples of endonucleases that co-authors of the DARPA grant used in previous work to make chimeric coronaviruses.
When present, the distribution of BsmBI and BsaI cut sites in viruses isolated from nature (e.g., SARS-CoV-1) are randomly distributed throughout the genome. Meanwhile, the distribution of cut sites in SARS-CoV-2 appears to be non-random and suggests genetic manipulation in a laboratory (Fig. 3). Curiously, a previous study involving EcoHealth Alliance described the insertion of two BsaI cut sites in a bat coronavirus called “WIV1” (i.e., Wuhan Institute of Virology 1), allowing scientists to make changes to the spike protein (see S9 Fig. Spike substitution strategy).
Two BsaI cut sites can be found in the SARS-CoV-2 genome (Fig. 3) in the same location as BsaI cut sites engineered into WIV1 back in 2017. The astronomical odds of this being coincidence cannot be overstated. According to the authors, “BsaI or BsmBI sites were introduced into the [spike]. Then any spike could be substituted into the genome of [lab engineered WIV1] through this strategy.” The same strategy might have been used in the construction of what would become the SARS-CoV-2 genome.
Fig. 3. Distribution of BsmBI and BsaI cut sites in the genomes of the two pandemic SARS viruses. SARS-CoV-1 is a natural virus with cut sites that are randomly distributed, while distribution of cut sites in the SARS-CoV-2 genome appear to be non-random. The black bar represents the location of the spike gene; the FCS region is highlighted in red. BsaI can be used to cut out and replace most of the SARS-CoV-2 spike, including FCS, to alter virus infectivity.
Strong circumstantial evidence supports the lab- leak hypothesis
Three years into the current pandemic, with thousands of animals sampled and millions of genome sequences analyzed, nothing close to SARS-CoV-2 has been found in nature. In stark contrast to 2003-2004, China’s early response to COVID-19 was “disappearing” scientists and journalists, obfuscation, and deflecting blame for starting the pandemic away from themselves onto everything from the US Army to imported frozen fish. This is exactly the type of behavior you might expect from a guilty party.
No one (except maybe the dishonest Chinese government) has ever denied that the epicenter of the COVID-19 pandemic is Wuhan, China. But what are the odds that such an explosive outbreak originated at the Wuhan market? This is just one market out of about 40,000 markets scattered around China, and it happens to be a few miles away from a lab that in 2017 became the first high-security virology lab on the Chinese mainland.
Here, a counterargument is that SARS-CoV-1 was a natural spillover from a market, so there’s precedence. But even the far less transmissible SARS-CoV-1, not long after being brought into the lab for study, eventually “leaked” with fatal consequences.
The origin of SARS-CoV-2 is the most important question of the pandemic, with implications that extend exponentially beyond scoring political points. At the start of the pandemic, even the journal Nature was sounding the alarm about the increasing role China’s military has been playing in secretive biomedical research in China. Yet, three years later all we have is obfuscation from China and Fauci and nothing even close to a natural ancestor of SARS-CoV-2. Throughout the pandemic, people parroted empty phrases like “Follow the science” without really following the science.
So, let’s do that, let’s “Follow the science” (and the logic), because the genetic and circumstantial evidence for a lab leak is impossible for any reasonable person to deny.
* * *
Pat Fidopiastis is a Professor of Microbiology at California Polytechnic State University,
Another ominous fact is the vaxed can shed some of the CV19 bioweapon poison onto people who are unvaxed. This is called “shedding” or “transmission.” Eads explains, “It’s really not shedding. It’s really transmission or transfection of spike proteins. The spike protein is made up of virus inside it. It has HIV and the Glyco-spike protein . . . .It can be shed from the nose or the mouth . . . and by skin-on-skin contact, and that’s been well documented by Dr. Ryan Cole and Dr. Peter McCullough. . . It is documented that there is no end point right now to stop the creation of the spike protein (in the vaxed).”
CV19 bioweapon vax truth warrior Dr. Betsy Eads has been warning of a “Tsunami of ‘vaccine’ deaths coming in the next two years.” The number of people dying and getting permanent disabilities is increasing. That is no surprise with 600 million CV19 injections being administered in America alone. There have been about 13 billion CV19 injections given worldwide. The estimation of the dead and permanently disabled is stunning and criminal. Dr. Eads explains, “In my personal opinion that a billion people will either die or be permanently disabled. A new “Expose” article shows 5,162% increase in deaths (in Australia) from this bioweapon shot since 2020. . . . Those are just stunning numbers, and we are seeing it all over the world. From the UK that is on shot number 6, to Israel that is on shot 7 with complete medical chipping. . . . The entire country of Israel is now medically chipped with portable medical records and vaccine records. . . . We are seeing death and permanent disability in huge numbers. It is causing huge increases in all-cause mortality. Just look at Ed Dowd’s numbers. They are as high as 40% (increase of all-cause mortality) in that young working category. We have never seen this many death and disability numbers. There are over 7,000 a day, in America, with death and disability – a day. This is incredible. The CV19 injections are a true bioweapon. . . . this was never a vaccine, it has always been a bioweapon.”
Another ominous fact is the vaxed can shed some of the CV19 bioweapon poison onto people who are unvaxed. This is called “shedding” or “transmission.” Eads explains, “It’s really not shedding. It’s really transmission or transfection of spike proteins. The spike protein is made up of virus inside it. It has HIV and the Glyco-spike protein . . . .It can be shed from the nose or the mouth . . . and by skin on skin contact, and that’s been well documented by Dr. Ryan Cole and Dr. Peter McCullough. . . It is documented that there is no end point right now to stop the creation of the spike protein (in the vaxed).”
In other words, spike protein cannot be turned off, and this poison can be transmitted from the vaxed to the unvaxed. People suffering from the effects of shedding can suffer some of the same illnesses as the vaccinated.
Here’s the good news. Dr. Eads and other top doctors have developed treatments that can remove the spike proteins and dramatically lessen the effects of the CV19 bioweapon. There is no cure, but the top three treatments Dr. Eads recommends are Ivermectin (IVM), Hydroxychloroquine (HCQ) and Chlorine Dioxide (CD). Eads and other doctors have several other very helpful treatments, as well, with more being developed all the time. Dr. Eads talks about them in this 1-hour and 2-minute in-depth interview.
Dr. Eads says, “Absolutely, there is hope. These products are working. We are coming out with new products, and we are studying and coming out with new products every day. . . . God made your body so it can heal. Pray for forgiveness to God for taking the jab, and you need to be getting on these products to give your body a chance to heal.”
Join Greg Hunter as he talks to 25-year veteran Dr. Elizabeth Eads, DO, as she continues to highlight the unstoppable deaths and permanent injuries and offers hope and treatments to for the CV19 bioweapon vax.
There are 55 documented cases of performers collapsing, dying, or falling ill in late 2022 through 2023 in this video.
And in almost all of these cases, the media will say: “We don’t know what caused this, but it was definitely not the COVID vaccine.”
Really? And we saw this happening prior to the roll-outs of the COVID “vaccines”? Did we see this in 2020 during the height of the COVID “virus pandemic” when they said we would see people dropping dead on the streets because the COVID “virus” was so bad?
No, we did not see this. This began later in 2021, and continued throughout 2022 after the shots had been injected into the majority of the population.
New data shows that 100% of COVID deaths in Canada are being caused by the mRNA vaccines that were forced on the population by the Trudeau regime and Big Pharma.
New data shows that 100% of COVID deaths in Canada are being caused by the mRNA vaccines that were forced on the population by the Trudeau regime and Big Pharma.
Covid deaths in Canada doubled in 2022 with a 85% vaccinated population.
Health Canada reports Covid deaths week-by-week, starting from the beginning of the pandemic in 2020.
In 2020, the total Covid deaths reported to the Public Health Agency Canada by provinces and territories was 9,225.
In 2021, as vaccines became accessible to Canadians between January and July, Covid deaths didn’t decrease over the year. Instead, the figure slightly increased to 9,934.
And, in 2022, with an approximately 85% vaccinated population in January and a less deadly Covid variant dominant, Covid deaths increased again.
Over 2022, Health Canada data shows 15,844 deaths occurred due to Covid – almost double the number of deaths in 2020 when citizens were “unprotected.”
Over half of these reported deaths between 2020 and 2022 were among Canadians aged 80 years and older.
Health Canada no longer provides data on death by vaccination status. As such, there’s no way to decipher which deaths in 2022 were among vaccinated populations and which were among unvaccinated.
The health agency does show overall death percentages by vaccine status from the start of the vaccine rollout in December 2020. This data reveals that just over half of all Covid deaths took place among those who received at least one Covid vaccine.
Legacy media created hysteria around the Delta variant in 2021, as the just-vaccinated population was learning they were not immune from getting infected with – or dying from – Covid.
Data suggested that the Delta variant was more contagious than the previously dominant Alpha, but less deadly. Furthermore, research indicates the Omicron variant – which became dominant in 2022 – is even less lethal than the Delta.
As previously reported by The Counter Signal, Canada’s 2022 excess deaths trajectory is on pace to shatter the total from 2021 – and obliterate that from 2020.
Excess deaths is the term that indicates whether a region had more or fewer deaths than expected, given demographics and historical trends. The figure helps calculate the true impact of a health crisis.
Health Canada data indicates 13,940 excess deaths took place in 2022 up to August 27.
By this same period in 2021, the total excess deaths was 10,406. In 2020, the total was 8,057.
In other words, as the percentage of Canadians “vaccinated” against Covid increased, so too did the excess death total and the Covid deaths.
“Our citizens should know the urgent facts…but they don’t because our media serves imperial, not popular interests. They lie, deceive, connive and suppress what everyone needs to know, substituting managed news misinformation and rubbish for hard truths…”—Oliver Stone
Tales from the Conspiratum 
